|
|
|
Stem Cell Related Patent Number US6923959
| Title: | Method of pre-inducing a state of immune tolerance before organ transplantation | | Inventors: | Habener, Joel F.; Newton Centre, MA, USA | | Summary: | Described herein is a method of treating a patient suffering from diabetes mellitus by isolating a nestin- or ABCG2-positive pancreatic stem cell from a pancreatic islet of a donor, and transferring the stem cell into the patient. The invention relates to methods and compositions for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Also described are properties of nestin which has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Further disclosed are methods by which nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain additional stem cells or pseudo-islet like structures. Methods are included for the ex vivo differentiation of the pancreatic stem cells, as are methods by which pancreatic stem cells can be expanded and transplanted into a patient in need of such therapy, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells. | | Abstract: | Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6923959 | | Application Number: | US2002000136891 | | Date Filed: | 02/05/2002 | | Date Published: | 02/08/2005 | | Assignee: | The General Hospital Corporation, Boston, MA, USA |
|
|
